Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT6005 Phase I in Advanced Solid Tumors
NCT05116709Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Nov 2021
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BAT6005 in Advanced Malignant Solid Neoplasm (AMSN), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose-limiting toxicity at 21 days and Maximum Tolerated Dose at 21 days. Started Nov 2021; status: completed.
02
Drugs
BAT6005
03
Conditions
Advanced Malignant Solid Neoplasm (AMSN)
Beyond the preview
Go deeper on NCT05116709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116709.